Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · Real-Time Price · USD
8.81
0.00 (0.00%)
At close: Dec 5, 2025, 4:00 PM EST
9.08
+0.27 (3.06%)
After-hours: Dec 5, 2025, 7:01 PM EST
Corvus Pharmaceuticals Employees
Corvus Pharmaceuticals had 31 employees as of December 31, 2024. The number of employees increased by 3 or 10.71% compared to the previous year.
Employees
31
Change (1Y)
3
Growth (1Y)
10.71%
Revenue / Employee
n/a
Profits / Employee
-$486,290
Market Cap
657.95M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
CRVS News
- 4 weeks ago - Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 weeks ago - Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 5 weeks ago - Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 - GlobeNewsWire
- 7 weeks ago - Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 - GlobeNewsWire
- 2 months ago - Corvus Pharmaceuticals Appoints David Moore to Board of Directors - GlobeNewsWire
- 4 months ago - Corvus Pharmaceuticals: Positive Phase 1 Soquelitiinb Trial Data Brings 2025 Catalysts - Seeking Alpha
- 4 months ago - Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript - Seeking Alpha